130 related articles for article (PubMed ID: 21061794)
21. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
[TBL] [Abstract][Full Text] [Related]
22. Intratumoral effects of medroxy-progesterone on proliferation, apoptosis, and sex steroid receptors in endometrioid endometrial adenocarcinoma.
Dahmoun M; Boman K; Cajander S; Bäckström T
Gynecol Oncol; 2004 Jan; 92(1):116-26. PubMed ID: 14751147
[TBL] [Abstract][Full Text] [Related]
23. Do estrogen, progesterone, P53 and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis?
Gülseren V; Kocaer M; Özdemir İA; Çakır İ; Sancı M; Güngördük K
Curr Probl Cancer; 2020 Feb; 44(1):100498. PubMed ID: 31395281
[TBL] [Abstract][Full Text] [Related]
24. A prospective investigation of fluorescence imaging to detect sentinel lymph nodes at robotic-assisted endometrial cancer staging.
Paley PJ; Veljovich DS; Press JZ; Isacson C; Pizer E; Shah C
Am J Obstet Gynecol; 2016 Jul; 215(1):117.e1-7. PubMed ID: 26743505
[TBL] [Abstract][Full Text] [Related]
25. Patterns of episialin/MUC1 expression in endometrial carcinomas and prognostic relevance.
Sivridis E; Giatromanolaki A; Koukourakis MI; Georgiou L; Anastasiadis P
Histopathology; 2002 Jan; 40(1):92-100. PubMed ID: 11903603
[TBL] [Abstract][Full Text] [Related]
26. [Immunohistochemical markers expression in hysteroscopy and hysterectomy specimens from endometrial cancer patients: comparison].
Pilka R; Marková I; Dusková M; Zapletalová J; Tozzi M; Kudela M
Ceska Gynekol; 2010 May; 75(3):165-70. PubMed ID: 20731294
[TBL] [Abstract][Full Text] [Related]
27. L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion.
de Freitas D; Aguiar FN; Anton C; Bacchi CE; Carvalho JP; Carvalho FM
PLoS One; 2018; 13(12):e0209294. PubMed ID: 30557309
[TBL] [Abstract][Full Text] [Related]
28. L-type amino acid transporter 1 expression increases in well-differentiated but decreases in poorly differentiated endometrial endometrioid adenocarcinoma and shows an inverse correlation with p53 expression.
Watanabe J; Yokoyama Y; Futagami M; Mizunuma H; Yoshioka H; Washiya K; Hana K; Endou H; Okayasu I
Int J Gynecol Cancer; 2014 May; 24(4):659-63. PubMed ID: 24694899
[TBL] [Abstract][Full Text] [Related]
29. Evolution in endometrial cancer: evidence from an immunohistochemical study.
Vandenput I; Trovik J; Leunen K; Wik E; Stefansson I; Akslen L; Moerman P; Vergote I; Salvesen H; Amant F
Int J Gynecol Cancer; 2011 Feb; 21(2):316-22. PubMed ID: 21734474
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcomes of therapeutic pelvic lymphadenectomy for stage I endometrial adenocarcinoma.
Mohan DS; Samuels MA; Selim MA; Shalodi AD; Ellis RJ; Samuels JR; Yun HJ
Gynecol Oncol; 1998 Aug; 70(2):165-71. PubMed ID: 9740684
[TBL] [Abstract][Full Text] [Related]
31. Impact of oestrogen and progesterone receptor expression in the cancer cells and myometrium on survival of patients with endometrial cancer.
Tomica D; Ramić S; Danolić D; Šušnjar L; Perić-Balja M; Puljiz M
J Obstet Gynaecol; 2018 Jan; 38(1):96-102. PubMed ID: 28764605
[TBL] [Abstract][Full Text] [Related]
32. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Giordano G; Gnetti L; Merisio C; Melpignano M
Maturitas; 2007 Feb; 56(2):190-7. PubMed ID: 16963204
[TBL] [Abstract][Full Text] [Related]
33. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial.
Eltabbakh GH; Piver MS; Hempling RE; Shin KH
Int J Radiat Oncol Biol Phys; 1997 May; 38(2):373-80. PubMed ID: 9226326
[TBL] [Abstract][Full Text] [Related]
34. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinoma.
Sakuragi N; Hareyama H; Todo Y; Yamada H; Yamamoto R; Fujino T; Sagawa T; Fujimoto S
Acta Obstet Gynecol Scand; 2000 Apr; 79(4):311-6. PubMed ID: 10746848
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity.
Yamauchi N; Sakamoto A; Uozaki H; Iihara K; Machinami R
Int J Gynecol Pathol; 1996 Jul; 15(3):202-8. PubMed ID: 8811380
[TBL] [Abstract][Full Text] [Related]
37. p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy.
Bonfitto VL; de Angelo Andrade LA
Sao Paulo Med J; 2003 Jul; 121(4):163-6. PubMed ID: 14595509
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator.
Shih HC; Shiozawa T; Kato K; Imai T; Miyamoto T; Uchikawa J; Nikaido T; Konishi I
Hum Pathol; 2003 May; 34(5):471-8. PubMed ID: 12792921
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological risk factors for pelvic lymph node metastasis in clinical early-stage endometrioid endometrial adenocarcinoma.
Zhang C; Wang C; Feng W
Int J Gynecol Cancer; 2012 Oct; 22(8):1373-7. PubMed ID: 22932266
[TBL] [Abstract][Full Text] [Related]
40. Glycoprotein CD44 expression in normal, hyperplasic and neoplastic endometrium. An immunohistochemical study including correlations with p53, steroid receptor status and proliferative indices (PCNA, MIB1).
Zagorianakou N; Ioachim E; Mitselou A; Kitsou E; Zagorianakou P; Stefanaki S; Makrydimas G; Agnantis NJ
Eur J Gynaecol Oncol; 2003; 24(6):500-4. PubMed ID: 14658589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
